Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00114816
Status:
COMPLETED
Last Update Posted:
2007-05-21
First Post:
2005-06-17
Brief Title:
Docetaxel Followed by CEF Cyclophosphamide Epirubicin and 5-Fluorouracil Compared to Docetaxel and Capecitabine Followed by CEX Cyclophosphamide Epirubicin and Capecitabine as Adjuvant Treatment for Breast Cancer
Sponsor:
Finnish Breast Cancer Group
Organization:
Finnish Breast Cancer Group
Organization Data
Organization:
Finnish Breast Cancer Group
Class:
OTHER
Study ID:
FBCG Protocol No 01-2003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Finnish Breast Cancer Group
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
| Hoffmann-La Roche | INDUSTRY |
| Sanofi | INDUSTRY |